Journal of Clinical Oncology · 2023 · 69 citations · 28 references
MedicineOncologyPharmacotherapyGenitourinary OncologyOncology PharmacotherapyTumor ProgressionCancer ImmunotherapyGenitourinary Cancer PharmacotherapyImmunotherapy For Genitourinary CancersMalignant NeoplasmsPenile CancerRadiation TherapyAtezolizumab TherapyDisease-free Survival AnalysisImmunotherapy For Penile CancerPenile Cancer BiomarkersPenile Cancer PrognosisPenile Cancer RadiotherapyPhase Ii InvestigationSerious Adverse Events
PURPOSE: Patients with advanced penile squamous cell carcinoma have a poor prognosis (21% 2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (anti-PD-L1) in patients with advanced penile cancer, with or without radiotherapy (RT). PATIENTS AND METHODS: A single-center, nonrandomized phase II study with two treatment arms was conducted in 32 patients with histologically confirmed advanced penile cancer. All patients received atezolizumab (1,200 mg) once every 3 weeks. Twenty patients, who were expected to benefit from RT for locoregional disease control, received additional irradiation. The primary end point was 1-year progression-free survival (PFS) for the complete cohort and was reached if the actual 1-year PFS was at least 35%. Secondary end points included OS, objective response rate (ORR), and tolerability. Exploratory biomarker analyses were conducted in pretreatment specimens. RESULTS: = .037). CONCLUSION: T-cell infiltration, may help to better select responders.
28
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations
Medicine, Immunology, Oncology +17
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost, Ansuman T. Satpathy, Daniel K. Wells et al. · Nature Medicine · 2019 · 1.5K citations
Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 992 citations
Medicine, Oncology, Pharmacotherapy +17